Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijrobp.2024.06.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling rare metastasis in prostate cancer: The role of PSMA-PET and MRI in detecting penile involvement - A case report and literature review.
Urol Case Rep
November 2025
Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità University Hospital, 28100, Novara, Italy.
The aim of this study is to report a case of penile metastasis from prostate carcinoma, as it represents a very rare occurrence that clinicians should be aware of. We report a case of a 68-year-old patient affected by prostate cancer who has performed a PSMA-PET after radical prostatectomy for PSA elevation, which revealed a suspected uptake in the corpora cavernosa and corpora spongiosum, followed by multiparametric MRI examination with focus on penile involvement.
View Article and Find Full Text PDFPET/CT in breast cancer.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
September 2025
Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Madrid, Spain; Grupo de Trabajo de Oncología de la SEMNIM, Spain.
Breast cancer is one of the most prevalent neoplasms worldwide, with molecular subtypes that influence prognosis and therapeutic strategies. PET/CT with different radiopharmaceuticals has revolutionized diagnosis, staging, and treatment monitoring. [F]-Fluorodeoxyglucose remains the most widely used radiotracer, but it has limitations in certain subtypes, such as invasive lobular carcinoma, where 16α-[F] fluoro-17β-estradiol and [Ga]-FAPI (fibroblast activation protein inhibitors) have demonstrated greater utility.
View Article and Find Full Text PDFDiagnostic performance of Ga-PSMA-11 PET/MRI in biochemical recurrent prostate cancer after radical prostatectomy and prediction nomogram.
Urol Oncol
September 2025
Faculty of Medicine, Department of Nuclear Medicine, Gazi University, Beşevler Ankara, Turkey.
Background: This study aimed to evaluate the diagnostic performance of Ga-PSMA-11 PET/MRI in prostate cancer (PC) with biochemical recurrence (BCR) after radical prostatectomy (RP). It was also aimed to develop a nomogram to predict PET/MRI positivity.
Methods: The data of 140 PC patients who underwent Ga-PSMA-11 PET/MRI for BCR after RP were retrospectively analyzed.
First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.
Nuklearmedizin
September 2025
Nuclear Medicine, Ulm University Hospital, Ulm, Germany.
Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.
View Article and Find Full Text PDFThe Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
J Urol
September 2025
Department of Urology, Austin Health, Melbourne, Victoria, Australia.
Purpose: Prostate-specific membrane antigen positron emission tomography (PSMA PET) is increasingly used to diagnose and stage prostate cancer. A PRIMARY score uses anatomical localization and uptake patterns to improve diagnostic accuracy. We evaluated the histopathology of patients with no uptake pattern (PRIMARY score 1) and the prevalence of intraductal carcinoma of the prostate (IDC-P) in this subset compared with those with an uptake pattern (PRIMARY score ≥ 2).
View Article and Find Full Text PDF